Tuberc Respir Dis.  2018 Jul;81(3):256-257. 10.4046/trd.2018.0033.

Does the GOLD 2017 Classification Improve the Ability to Predict Exacerbation and Mortality?

• Hwang HG

• KMID: 2414569
• DOI: http://doi.org/10.4046/trd.2018.0033

Abstract

No abstract available.

MeSH Terms

Classification*
Mortality*

Reference

1. World Health Organization. Projections of mortality and causes of death, 2015 and 2030 [Internet]. Genava: World Health Organization;cite 2018 Mar 5. Available from: http://www.who.int/healthinfo/global_burden_disease/projections/en/.

2. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017; 5:691–706.

3. Connors AF Jr, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med. 1996; 154(4 Pt 1):959–967.

4. Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. Lancet. 2006; 367:1216–1219.

5. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017; 195:557–582.

6. Soriano JB, Lamprecht B, Ramirez AS, Martinez-Camblor P, Kaiser B, Alfageme I, et al. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Respir Med. 2015; 3:443–450.

7. Lange P, Tottenborg SS, Sorknaes AD, Andersen JS, Sogaard M, Nielsen H, et al. Danish Register of chronic obstructive pulmonary disease. Clin Epidemiol. 2016; 8:673–678.

8. Leivseth L, Brumpton BM, Nilsen TI, Mai XM, Johnsen R, Langhammer A. GOLD classifications and mortality in chronic obstructive pulmonary disease: the HUNT Study, Norway. Thorax. 2013; 68:914–921.

9. Johannessen A, Nilsen RM, Storebo M, Gulsvik A, Eagan T, Bakke P. Comparison of 2011 and 2007 Global Initiative for Chronic Obstructive Lung Disease guidelines for predicting mortality and hospitalization. Am J Respir Crit Care Med. 2013; 188:51–59.

10. Agusti A, Edwards LD, Celli B, Macnee W, Calverley PM, Mullerova H, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J. 2013; 42:636–646.

11. Candemir I, Ergun P, Kaymaz D, Tasdemir F, Egesel N. The comparison of clinical variables in two classifications: GOLD 2017 combined assessment and spirometric stage of chronic obstructive pulmonary disease. Tuberc Respir Dis. 2018; 03. 07. DOI: 10.4046/trd.2017.0114. [Epub].

12. Menezes AM, Wehrmeister FC, Perez-Padilla R, Viana KP, Soares C, Mullerova H, et al. The PLATINO study: description of the distribution, stability, and mortality according to the Global Initiative for Chronic Obstructive Lung Disease classification from 2007 to 2017. Int J Chron Obstruct Pulmon Dis. 2017; 12:1491–1501.

13. Kahnert K, Alter P, Young D, Lucke T, Heinrich J, Huber RM, et al. The revised GOLD 2017 COPD categorization in relation to comorbidities. Respir Med. 2018; 134:79–85.

14. Gedebjerg A, Szepligeti SK, Wackerhausen LH, Horvath-Puho E, Dahl R, Hansen JG, et al. Prediction of mortality in patients with chronic obstructive pulmonary disease with the new Global Initiative for Chronic Obstructive Lung Disease 2017 classification: a cohort study. Lancet Respir Med. 2018; 6:204–212.

15. Singh D, D'Urzo AD, Chuecos F, Munoz A, Garcia Gil E. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. Respir Res. 2017; 18:106.